We are a clinical stage oncology company leveraging our unique precision medicine platform, called Acrivon Predictive Precision Proteomics (AP3), for development of our drug pipeline. AP3 is used to generate proprietary OncoSignature® companion diagnostics to identify the patients who will benefit from our medicines. The name Acrivon (derived from Greek for “accurate”) embodies how our OncoSignature® tests link the patient’s active tumor-driving mechanisms with the drug’s mode-of-action to accurately match our therapies with patients who will benefit independent of underlying genetic tumor alterations. Our pipeline includes the advanced Phase 2 lead program, ACR-368 (prexasertib), a clinically active CHK1/2 inhibitor, as well as preclinical programs targeting critical nodes in DNA Damage Response (DDR) and cell cycle regulation.
About
Our Values
We value diversity, integrity, and passion for scientific excellence, and care deeply about our patients
Purpose
Rigor
Passion
Accountability
Perseverance
Creativity
Teamwork
Purpose
Rigor
Passion
Accountability
Perseverance
Creativity
Teamwork
Consider joining our team of driven & passionate pioneers
At Acrivon, we challenge you to become more.In addition to learning from some of the field’s greatest minds, our committed team members are encouraged to realize their full potential in work and life. We’re a passionate group that values openness, creativity, fresh perspectives, transformative ideas, and a positive can-do attitude.
If you have the drive and passion to build the future with us, please see our current open positions.
